Encompass Health Co. (NYSE:EHC) Shares Bought by Woodline Partners LP

Woodline Partners LP increased its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 44.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 184,473 shares of the company's stock after acquiring an additional 56,817 shares during the quarter. Woodline Partners LP owned about 0.18% of Encompass Health worth $17,036,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of EHC. Squarepoint Ops LLC increased its stake in Encompass Health by 599.0% during the 4th quarter. Squarepoint Ops LLC now owns 127,204 shares of the company's stock valued at $11,747,000 after purchasing an additional 109,007 shares in the last quarter. Twinbeech Capital LP purchased a new stake in Encompass Health during the fourth quarter worth $3,893,000. Two Sigma Advisers LP boosted its holdings in Encompass Health by 136.3% during the fourth quarter. Two Sigma Advisers LP now owns 63,800 shares of the company's stock worth $5,892,000 after buying an additional 36,800 shares in the last quarter. Two Sigma Investments LP lifted its holdings in Encompass Health by 149.5% during the fourth quarter. Two Sigma Investments LP now owns 302,317 shares of the company's stock valued at $27,919,000 after purchasing an additional 181,146 shares in the last quarter. Finally, Teza Capital Management LLC purchased a new position in Encompass Health during the fourth quarter valued at $1,128,000. Institutional investors own 97.25% of the company's stock.

Encompass Health Stock Up 1.5%

Encompass Health stock traded up $1.82 during trading on Tuesday, reaching $120.72. The stock had a trading volume of 99,196 shares, compared to its average volume of 787,133. The stock has a market cap of $12.17 billion, a PE ratio of 27.07, a P/E/G ratio of 2.31 and a beta of 0.91. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 52-week low of $82.74 and a 52-week high of $121.96. The business has a 50 day moving average price of $108.24 and a 200 day moving average price of $101.51.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The company's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.12 EPS. On average, analysts predict that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a $0.17 dividend. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.56%. Encompass Health's payout ratio is 14.05%.

Analyst Ratings Changes

EHC has been the topic of several research reports. Barclays raised their price target on shares of Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. UBS Group raised their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. William Blair reiterated an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. Truist Financial reiterated a "buy" rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Finally, Royal Bank of Canada raised their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, April 28th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $122.71.

Insider Activity

In other news, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total value of $1,147,900.00. Following the transaction, the executive vice president now directly owns 79,710 shares of the company's stock, valued at $9,149,910.90. The trade was a 11.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now directly owns 527,070 shares in the company, valued at $64,054,817.10. The trade was a 18.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock valued at $16,034,082 in the last ninety days. 2.00% of the stock is currently owned by company insiders.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.